Skip to content

Thrombus Aspiration During Percutaneous Coronary Intervention in Acute Non-ST-elevation Myocardial Infarction Study

Thrombus Aspiration During Percutaneous Coronary Intervention in Acute Non-ST-elevation Myocardial Infarction Study (TAPAS II)

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01013038
Acronym
TAPAS II
Enrollment
540
Registered
2009-11-13
Start date
2007-12-31
Completion date
2012-06-30
Last updated
2009-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-ST-Elevation Myocardial Infarction

Keywords

myocardial infarction, percutaneous coronary intervention, thrombus aspiration

Brief summary

In this trial, the investigators will evaluate the effect of thrombus aspiration followed by stent implantation in improving myocardial blush grade in patients with acute non-ST-elevation myocardial infarction compared to conventional percutaneous coronary intervention (PCI).

Detailed description

The Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS) has shown that thrombus aspiration improves myocardial perfusion and clinical outcome compared to conventional primary percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction. Impaired myocardial perfusion due to spontaneous or angioplasty-induced embolization of atherothrombotic material also occurs in patients with Non-ST-elevation myocardial infarction (NSTEMI). The aim of this study is to determine whether thrombus aspiration before stent implantation will result in improved myocardial perfusion in patients with NSTEMI compared to conventional PCI. The study is a single-centre, prospective, randomised trial with blinded evaluation of endpoints. The planned inclusion is 540 patients with acute NSTEMI who are candidates for urgent PCI. If thrombus aspiration leads to significant improvement of myocardial perfusion in patients with acute NSTEMI it may become part of the standard interventional approach.

Interventions

PROCEDUREThrombus aspiration followed by stent implantation

Export aspiration catheter 6F (Medtronics)

balloon angioplasty and/or stent implantation

Sponsors

Netherlands Heart Foundation
CollaboratorOTHER
University Medical Center Groningen
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosis of acute NSTEMI defined by * Chest pain suggestive for myocardial ischemia for at least 30 minutes, * Time from onset of symptoms of less than 72 hours * ECG with ST-segment shifts (depression of \>0.1 mV in at least two contiguous leads or transient ST-segment elevation \>0.1 mV in at least two contiguous leads for less than 30 minutes) and/or T-wave changes (inversion of \>0.15 mV in at least two contiguous leads) * Positive cardiac troponin T \>0,01 μg/L. * Clinical indication for urgent PCI of the ischemia-related target lesion as identified at coronary angiography

Exclusion criteria

* Persistent ST-elevation of more than 0.1 mV in 2 or more leads * Presence of cardiogenic shock * Inability to obtain informed consent * Known existence of a life-threatening disease with a life expectancy of less than 6 months

Design outcomes

Primary

MeasureTime frame
Incidence of myocardial blush grade 3 after PCIDuring PCI procedure

Secondary

MeasureTime frame
Coronary angiographic outcomesDuring PCI procedure
Histopathological outcomes of atherothrombotic materialAfter inclusion is stopped: mean 1 year (storage at -80 degrees Celcius)
Enzymatic infarct sizeDuring hospital stay
Electrocardiographic outcomes30 to 60 minutes after PCI
Clinical outcomes at 30 days and 1 year30 days till 1 year

Countries

Netherlands

Contacts

Primary ContactMarthe A Kampinga, MD
m.a.kampinga@thorax.umcg.nl+31503610444
Backup ContactFelix Zijlstra, MD PhD
f.zijlstra@thorax.umcg.nl+31503613238

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026